Maarten J Postma

Summary

Affiliation: University of Groningen
Country: The Netherlands

Publications

  1. ncbi [Opportunistic screening for genital infections with Chlamydia trachomatis among the sexually active population in Amsterdam. III. Cost-effectiveness analysis of screening women and the role of reinfection and partner treatment]
    M J Postma
    Groningen University Institute for Drug Exploration GUIDE Rijksuniversiteit, vakgroep Sociale Farmacie en Farmaco epidemiologie
    Ned Tijdschr Geneeskd 143:2383-5. 1999
  2. ncbi [Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis]
    M J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Antonius Deusinglaan 1, 9713 AV Groningen
    Ned Tijdschr Geneeskd 146:855-9. 2002
  3. ncbi Cost-effectiveness of leucocyte depletion of red-cell transfusions for patients undergoing cardiac surgery
    M J Postma
    Groningen University Institute for Drug Exploration/University of Groningen Institute of Pharmacy (GUIDE/GRIP, Groningen, The Netherlands
    Vox Sang 84:65-7. 2003
  4. ncbi Cost-effectiveness of periconceptional supplementation of folic acid
    M J Postma
    Groningen University, Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Pharm World Sci 24:8-11. 2002
  5. ncbi Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia Trachomatis
    M J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
    Value Health 4:266-75. 2001
  6. ncbi Do costs of varicella justify routine infant vaccination? Pharmacoeconomic and clinical considerations
    M J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy, 9713 AV Groningen, The Netherlands
    Eur J Health Econ 5:54-7. 2004
  7. ncbi Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes
    Maarten J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Department of Social Pharmacy, Pharmaco epidemiology and Pharmacotherapy, The Netherlands
    Expert Opin Pharmacother 4:1543-50. 2003
  8. ncbi Pharmacoeconomic research
    Maarten J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen, The Netherlands
    Pharm World Sci 25:245-6. 2003
  9. ncbi Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands
    M J Postma
    Groningen University Institute for Drug Exploration Groningen Research Institute of Pharmacy GUIDE GRIP, Groningen, The Netherlands
    Pharmacoeconomics 19:215-22. 2001
  10. ncbi Socio-economic aspects of extended STD screening in pregnancy
    M J Postma
    Groningen University for Drug Exploration GUIDE, Groningen, The Netherlands
    AIDS Care 12:731-5. 2000

Detail Information

Publications107 found, 100 shown here

  1. ncbi [Opportunistic screening for genital infections with Chlamydia trachomatis among the sexually active population in Amsterdam. III. Cost-effectiveness analysis of screening women and the role of reinfection and partner treatment]
    M J Postma
    Groningen University Institute for Drug Exploration GUIDE Rijksuniversiteit, vakgroep Sociale Farmacie en Farmaco epidemiologie
    Ned Tijdschr Geneeskd 143:2383-5. 1999
    ..From a pharmacoeconomic point of view partner treatment should be routinely provided in the framework of a CT screening programme for Amsterdam women...
  2. ncbi [Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis]
    M J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Antonius Deusinglaan 1, 9713 AV Groningen
    Ned Tijdschr Geneeskd 146:855-9. 2002
    ..To assess the cost-effectiveness of vaccination to prevent invasive pneumococcal disease in the elderly...
  3. ncbi Cost-effectiveness of leucocyte depletion of red-cell transfusions for patients undergoing cardiac surgery
    M J Postma
    Groningen University Institute for Drug Exploration/University of Groningen Institute of Pharmacy (GUIDE/GRIP, Groningen, The Netherlands
    Vox Sang 84:65-7. 2003
  4. ncbi Cost-effectiveness of periconceptional supplementation of folic acid
    M J Postma
    Groningen University, Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Pharm World Sci 24:8-11. 2002
    ..Supplementation of folic acid prior to and in the beginning of pregnancy may prevent neural tube defects (NTDs) in newborns--such as spina bifida--and possibly other congenital malformations...
  5. ncbi Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia Trachomatis
    M J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
    Value Health 4:266-75. 2001
    ..To assess the cost-effectiveness of pharmacotherapy for male partners in screening women for asymptomatic infection with Chlamydia trachomatis (CT)...
  6. ncbi Do costs of varicella justify routine infant vaccination? Pharmacoeconomic and clinical considerations
    M J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy, 9713 AV Groningen, The Netherlands
    Eur J Health Econ 5:54-7. 2004
  7. ncbi Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes
    Maarten J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Department of Social Pharmacy, Pharmaco epidemiology and Pharmacotherapy, The Netherlands
    Expert Opin Pharmacother 4:1543-50. 2003
    ..In particular, potential pharmacoeconomic implications and related methodological aspects of the recent RENAAL trial for losartan are considered...
  8. ncbi Pharmacoeconomic research
    Maarten J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen, The Netherlands
    Pharm World Sci 25:245-6. 2003
    ..How should we interpret such pharmacoeconomic studies? To enhance accurate interpretation of such studies among our readership, we present the basic concepts of pharmacoeconomics in this commentary...
  9. ncbi Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands
    M J Postma
    Groningen University Institute for Drug Exploration Groningen Research Institute of Pharmacy GUIDE GRIP, Groningen, The Netherlands
    Pharmacoeconomics 19:215-22. 2001
    ..To assess the cost effectiveness (net costs per life year gained) of pneumococcal vaccination of elderly individuals aged 65 years and over in The Netherlands...
  10. ncbi Socio-economic aspects of extended STD screening in pregnancy
    M J Postma
    Groningen University for Drug Exploration GUIDE, Groningen, The Netherlands
    AIDS Care 12:731-5. 2000
    ..Further research should be directed to the economic aspects of paediatric HIV infection and the epidemiology of CT in pregnancy...
  11. ncbi Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands
    Maarten J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Groningen, The Netherlands
    Expert Rev Vaccines 2:477-82. 2003
    ....
  12. ncbi Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence
    M J Postma
    Groningen University Institute for Drug Exploration Groningen Research Institute of Pharmacy The Netherlands
    Drugs Aging 17:217-27. 2000
    ..Relatively favourable cost-effectiveness among non-high-risk elderly justifies universal influenza vaccination of the elderly from a pharmacoeconomic point of view...
  13. ncbi [Pharmaco-economic evaluation of mandatory HIV-screening in pregnancy; a cost-efficacy analysis in Amsterdam]
    M J Postma
    Groningen University Institute for Drug Exploration, vakgroep Sociale Farmacie en Farmaco epidemiologie, Groningen
    Ned Tijdschr Geneeskd 144:749-54. 2000
    ..To estimate the cost effectiveness of universal screening for HIV of pregnant women in Amsterdam...
  14. ncbi Economic evaluation of influenza vaccination. Assessment for The Netherlands
    M J Postma
    National Institute of Public Health and the Environment, Bilthoven, The Netherlands
    Pharmacoeconomics 16:33-40. 1999
    ..The objective of this study was to determine the costs associated with influenza and the cost effectiveness (net costs per life-year gained) of influenza vaccination in The Netherlands...
  15. ncbi [Agreement between guidelines for pharmaco-economic research and never-before-published health-economics evaluations]
    M J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Antonius Deusinglaan 1, 9713 AV Groningen
    Ned Tijdschr Geneeskd 146:1082-7. 2002
    ....
  16. ncbi Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands
    Cornelis Boersma
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Clin Ther 32:1103-21. 2010
    ..Albuminuria is a marker for renal and cardiovascular (CV) risk, allowing early diagnosis of subjects with elevated renal and CV risk...
  17. ncbi Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the northern Netherlands between 2000 and 2006
    Hong Anh T Tu
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Clin Ther 32:133-44. 2010
    ..In addition, the duration of use and the costs of these treatments were investigated...
  18. ncbi Systematic screening for Chlamydia trachomatis: estimating cost-effectiveness using dynamic modeling and Dutch data
    Robin de Vries
    Groningen University Institute for Drug Exploration/University of Groningen Research Institute of Pharmacy, Groningen, The Netherlands
    Value Health 9:1-11. 2006
    ..A screening program consisting of screening women only should always be adopted from a pharmacoeconomic point of view. Our dynamic approach appreciates better the specific characteristics of an infectious disease, such as CT...
  19. ncbi Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data
    Cornelis Boersma
    Department of Pharmacy, Unit of PharmacoEpidemiology and PharmacoEconomics PE2, University of Groningen, Groningen, The Netherlands
    Am J Cardiovasc Drugs 10:49-54. 2010
    ....
  20. ncbi Cost-utility of repeated screening for Chlamydia trachomatis
    Robin de Vries
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy, Groningen, The Netherlands
    Value Health 11:272-4. 2008
    ..To estimate the cost-effectiveness of repeated screening for chlamydia trachomatis at various time intervals compared to one-off screening of Dutch young adults...
  21. ncbi Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands
    Marinus van Hulst
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Transfusion 49:2729-42. 2009
    ..This study attempted to accomplish this by providing an easy-to-use Web interface at http://www.bloodsafety.info that allows decision makers to adapt this model to local conditions...
  22. ncbi Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal
    Jarir Atthobari
    Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen UniversityInstitute for Drug Exploration, Groningen, The Netherlands
    Clin Ther 28:432-44. 2006
    ..However, confirmation from larger multicenter trials is needed...
  23. ncbi Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: the impact of varying the discount rate for health
    Robin de Vries
    Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Vaccine 27:846-52. 2009
    ..Furthermore, we showed the large impact of the discount rate for health on the cost-effectiveness of a HP vaccination program, illustrative for other vaccination programs...
  24. ncbi Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events
    Cornelis Boersma
    Groningen Research Institute of Pharmacy GRIP, University of Groningen, Groningen, The Netherlands
    Br J Clin Pharmacol 65:723-32. 2008
    ..It could therefore be expected that especially subjects with higher albuminuria levels may benefit from blood pressure-lowering agents to improve their cardiovascular outcome...
  25. ncbi Economic evaluations of rotavirus immunization for developing countries: a review of the literature
    Hong Anh T Tu
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 10:1037-51. 2011
    ....
  26. ncbi Economic evaluation of folic acid food fortification in The Netherlands
    Janneke Jentink
    Graduate Schools SHARE and GUIDE, Department of Social Pharmacy and Pharmacoepidemiology, University of Groningen, Groningen, The Netherlands
    Eur J Public Health 18:270-4. 2008
    ..We designed our study to estimate cost-effectiveness of folic acid food fortification in the Netherlands...
  27. ncbi Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands
    Jasper M Bos
    Department of Social Pharmacy, Pharmaco epidemiology and Pharmacotherapy, Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Groningen, The Netherlands
    Pharmacoeconomics 24:141-53. 2006
    ....
  28. ncbi Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: a study conducted for the Netherlands
    Cornelis Boersma
    Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen University for Drug Exploration GUIDE, Groningen, The Netherlands
    Appl Health Econ Health Policy 4:191-6. 2005
    ..However, drug costs may not decrease after patent expiry, because of a lack of price competition and different national pricing systems...
  29. ncbi Adherence of pharmacoeconomic studies to national guidelines in the Netherlands
    Jarir Atthobari
    Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen University Institute for Drug Exploration (GUIDE, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Pharm World Sci 27:364-70. 2005
    ..However, major improvements are required with respect to the adoption of the societal perspective, presentation of adequate subgroup analyses and application of reference prices...
  30. ncbi Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making
    Cornelis Boersma
    Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen University Institute for Drug Exploration GUIDE, Groningen, The Netherlands
    Pharmacoeconomics 24:523-35. 2006
    ..This will result in a proper pharmacoeconomic outcome, where both types of drugs can be compared for healthcare decisions...
  31. ncbi Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands
    G A A Hubben
    Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, University of Groningen, and Base Case, Healthcare Decision Support, Groningen, The Netherlands
    Vaccine 25:3669-78. 2007
    ....
  32. ncbi On discounting of health gains from human papillomavirus vaccination: effects of different approaches
    Tjalke A Westra
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Value Health 15:562-7. 2012
    ..Different approaches to discount health effects have been proposed. In this study, we estimated the impact of different approaches for discounting health benefits of human papillomavirus (HPV) vaccination...
  33. ncbi Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries
    Hong Anh T Tu
    Unit of PharmacoEpidemiology and PharmacoEconomics PE 2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Vaccine 30:1521-8. 2012
    ....
  34. ncbi Compliance, persistence, and switching patterns for ACE inhibitors and ARBs
    Stefan Vegter
    Unit of Pharmaco Epidemiology and PharmacoEconomics, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Am J Manag Care 17:609-16. 2011
    ..To investigate compliance, persistence, and switching patterns for angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs)...
  35. ncbi An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands
    Cornelis Boersma
    Groningen Research Institute of Pharmacy GRIP, University of Groningen, Groningen, The Netherlands
    Clin Ther 29:963-71. 2007
    ..Compared with atenolol, losartan reduced the combined risk for CVD-related morbidity and mortality by 13% (P = 0.021), and reduced the risk for stroke by 25% (P = 0.001), with comparable blood pressure control in both trial arms...
  36. ncbi Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence
    Petros Pechlivanoglou
    Department of Pharmacoepidemiology and Pharmacoeconomics PE2, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 29:737-51. 2011
    ..Furthermore, we show that the results of cost-effectiveness analyses are highly dependent on several crucial factors that influence the baseline IFI incidence rates and, therefore, differ per patient population or region...
  37. ncbi Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism
    Stefan Vegter
    Departments of Pharmacy, University Medical Centre Groningen, Groningen, The Netherlands
    Pharmacogenet Genomics 19:695-703. 2009
    ..Furthermore, we considered a selective screen-and-treat strategy in which patients are prescribed alternative, more effective, therapy based on their ACE (I/D) polymorphism...
  38. ncbi Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approach
    R Welte
    Department of Health Services Research, National Institute of Public Health and the Environment, Bilthoven, The Netherlands
    Sex Transm Dis 27:518-29. 2000
    ..Models commonly used for the economic assessment of chlamydial screening programs do not consider population effects...
  39. ncbi Cost-effectiveness of HIV screening of blood donations in Accra (Ghana)
    Marinus van Hulst
    Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
    Value Health 11:809-19. 2008
    ....
  40. ncbi Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections
    Robin de Vries
    Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 26:75-90. 2008
    ..As the diagnosis of invasive fungal infections is difficult, effective antifungal prophylaxis is desirable. So far, fluconazole has been the most commonly used...
  41. ncbi Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults
    Maarten J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute for Pharmacy GUIDE GRIP, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Vaccine 23:5365-71. 2005
    ..To assess the economic implications of strategies for influenza control among healthy working adults in The Netherlands...
  42. ncbi Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination
    Mark H Rozenbaum
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 10:187-99. 2011
    ..We conclude that the health and economic impact should be addressed in light of the country specific pneumoccocal disease epidemiology to support decisions on immunization programs...
  43. ncbi Economic evaluation of a randomized trial comparing Helicobacter pylori test-and-treat and prompt endoscopy strategies for managing dyspepsia in a primary-care setting
    Rogier M Klok
    Groningen University Institute for Drug Exploration, Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, The Netherlands
    Clin Ther 27:1647-57. 2005
    ..We performed an economic analysis of a Helicobacter pylori test-and-treat strategy versus a prompt endoscopy approach in a primary care setting...
  44. ncbi Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands
    Maarten J Postma
    Graduate Schools SHARE and GUIDE, Groningen Research Institute of Pharmacy GRIP, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 25:497-509. 2007
    ..Oseltamivir is effective in the treatment of influenza. Utilisation in The Netherlands is limited, but increasing...
  45. ncbi Comparative model-based analysis of screening programs for Chlamydia trachomatis infections
    M Kretzschmar
    Department of Infectious Disease Epidemiology, National Institute of Public Health and the Environment RIVM, Bilthoven, The Netherlands
    Am J Epidemiol 153:90-101. 2001
    ..Partner referral contributes substantially to prevalence reduction...
  46. ncbi Cost-effectiveness estimates for antenatal HIV testing in the Netherlands
    M H Rozenbaum
    Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Int J STD AIDS 19:668-75. 2008
    ..We show that universal HIV screening during pregnancy generates significant net cost savings and health benefits in most situations. Universal antenatal HIV screening is justified in Amsterdam from a health-economic point of view...
  47. ncbi A systematic review on the application of cardiovascular risk prediction models in pharmacoeconomics, with a focus on primary prevention
    Jelena Stevanovic
    Department of Pharmacoepidemiology and Pharmacoeconomics PE2, University of Groningen, Antonius Deusinglaan 1, Groningen, The Netherlands
    Eur J Prev Cardiol 19:42-53. 2012
    ..In this article, we summarize the literature on the application of these risk models in pharmacoeconomic studies for primary cardiovascular disease prevention interventions in high-income countries...
  48. ncbi Comparatively low attendance during Human Papillomavirus catch-up vaccination among teenage girls in the Netherlands: Insights from a behavioral survey among parents
    Giedre Gefenaite
    Department of Pharmacy, PharmacoEpidemiology and PharmacoEconomics PE2, University of Groningen, Groningen, The Netherlands
    BMC Public Health 12:498. 2012
    ..The Dutch Human Papillomavirus (HPV) catch-up vaccination program in 2009 appeared less successful than expected. We aimed to identify the most important determinants of refusing the vaccination...
  49. ncbi [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses]
    Tjalke A Westra
    Universitair Medisch Centrum Groningen, Afd Medische Microbiologie, sectie Moleculaire Virologie, Groningen, The Netherlands
    Ned Tijdschr Geneeskd 153:A356. 2009
    ..The actual health benefits gained by HPV vaccination are strongly dependent on vaccination coverage. It is therefore important that this remains high (85-100%)...
  50. ncbi Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands
    Adrianne Faber
    Groningen University Institute for Drug Exploration, University of Groningen, Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen, The Netherlands
    CNS Drugs 22:157-70. 2008
    ..Stimulants are the drugs of first choice in the treatment of ADHD. It has been suggested that full costs associated with the treatment of ADHD may be reduced by once-daily administration regimens of stimulants...
  51. ncbi Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar)
    Mark H Rozenbaum
    Unit of PharmacoEpidemiology and PharmacoEconomics PE 2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Vaccine 28:2367-9. 2010
    ....
  52. ncbi Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs
    Anna K Lugnér
    National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Epidemiology and Surveillance, Bilthoven, The Netherlands
    Eur J Public Health 19:516-20. 2009
    ..If the stockpile would be used in relation to the recent pandemic alert, an investment decision about renewing the stock for a possible subsequent pandemic is essential. The decision should include cost-effectiveness considerations...
  53. ncbi Cost-effectiveness of varicella vaccination programs: an update of the literature
    Mark H Rozenbaum
    Groningen Research Institute of Pharmacy GRIP, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Expert Rev Vaccines 7:753-82. 2008
    ..Despite that, those aspects limit the timeliness of our review and we believe that the current work does provide useful insights in the cost-effectiveness of varicella vaccination...
  54. ncbi Health economics of blood transfusion safety--focus on sub-Saharan Africa
    Marinus van Hulst
    Unit of PharmacoEpidemiology and PharmacoEconomics PE 2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Biologicals 38:53-8. 2010
    ..This review discusses the health economic evaluations of strategies to enhance blood product safety in sub-Saharan Africa...
  55. ncbi Cost-effectiveness of widespread screening for Chlamydia trachomatis
    Maarten J Postma
    Groningen University Institute for Drug Exploration/University of Groningen Research Institute of Pharmacy (GUIDE/GRIP, Groningen, The Netherlands
    Expert Opin Pharmacother 3:1443-50. 2002
    ..Illustrations are drawn from recent work in The Netherlands, which may also be representative for other settings...
  56. ncbi Discounting health effects in pharmacoeconomic evaluations: current controversies
    J M Bos
    Groningen, University Institute for Drug Exploration, Department of Social Pharmacy, Pharmacoepidemiology, Groningen, The Netherlands
    Pharmacoeconomics 23:639-49. 2005
    ..Instead, results should be presented in a non-aggregated manner that enables policy makers to value health gains according to timing and to which subpopulation they are accrued in...
  57. ncbi Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence
    Maarten J Postma
    Groningen University Institute for Drug Exploration / University of Groningen Research Institute of Pharmacy (GUIDE/GRIP, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Drugs 62:1013-24. 2002
    ..Pharmacoeconomics do, however, present only one argument for consideration aside from ethical issues, budgetary limits and psychosocial aspects...
  58. ncbi Health economic methodology illustrated with recent work on Chlamydia screening: the concept of extended dominance
    M J Postma
    Groningen Research Institute of Pharmacy GRIP, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
    Sex Transm Infect 84:152-4. 2008
    ....
  59. ncbi Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes
    Janneke Jentink
    University of Groningen, Groningen, The Netherlands
    J Med Econ 15:862-8. 2012
    ..In particular, to estimate the impact of teratogenicity on the costs per quality adjusted life year (QALY)...
  60. ncbi Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands
    Maarten J Postma
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    J Med Econ 15:878-86. 2012
    ....
  61. ncbi Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands
    Tjalke A Westra
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Antonius Deusinglaan 1, 9713AV, Groningen, The Netherlands
    BMC Infect Dis 13:75. 2013
    ..In this study, we made an analytical comparison of the two vaccines in terms of cost-effectiveness including the additional benefits of cross-protection and protection against genital warts in comparison with a screening-only strategy...
  62. ncbi A review of the literature on the economics of vaccination against TB
    Hong Anh T Tu
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 11:303-17. 2012
    ....
  63. ncbi Cost considerations in the treatment of colorectal cancer
    Frank G A Jansman
    Groningen University Institute for Drug Exploration, Department of Pharmacotherapy and Pharmaceutical Care, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 25:537-62. 2007
    ....
  64. ncbi [Influenza vaccination of hospital healthcare staff from the perspective of the employer: a positive balance]
    Eelko Hak
    Rijksuniversiteit Groningen, Groningen Research Institute for Pharmacy GRIP, unit Farmaco epidemiologie and Farmaco economie FE2, Groningen, The Netherlands
    Ned Tijdschr Geneeskd 154:A1188. 2010
    ..To assess the annual productivity loss among hospital healthcare workers attributable to influenza and to estimate the costs and economic benefits of a vaccination programme from the perspective of the the employer...
  65. ncbi Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations
    Stefan Vegter
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Clin Ther 32:1651-61. 2010
    ....
  66. ncbi Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands
    Petros Pechlivanoglou
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Clin Ther 32:108-18. 2010
    ....
  67. ncbi Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world
    Maarten J Postma
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
    BMC Med 9:84. 2011
    ....
  68. ncbi Mitigation of pandemic influenza: review of cost-effectiveness studies
    Anna K Lugnér
    RIVM National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Epidemiology and Surveillance Unit, Bilthoven, The Netherlands
    Expert Rev Pharmacoecon Outcomes Res 9:547-58. 2009
    ....
  69. ncbi Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases
    Jasper M Bos
    Groningen University Institute for Drug Exploration, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 22:1171-9. 2004
    ..A numerical example illustrates our approach. We discuss the associated potential implications for public health policy and discuss how the effects of the intervention can be additionally corrected for societal preferences...
  70. ncbi Pharmaco-economics of blood transfusion safety: review of the available evidence
    M van Hulst
    Department of Social Pharmacy, Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Vox Sang 83:146-55. 2002
    ..This review discusses the pharmaco-economic evaluations of strategies to enhance blood product safety that have been published in the scientific literature...
  71. ncbi Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands
    Jasper M Bos
    Department of Social Pharmacy, Groningen University Institute for Drug Exploration Groningen Research Institute for Pharmacy, University Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Clin Ther 25:2614-30. 2003
    ..These diseases lead to substantial mortality, morbidity, and costs. The societal impact is especially severe because most cases occur in very young infants...
  72. ncbi The economics of HIV vaccines: projecting the impact of HIV vaccination of infants in sub-Saharan Africa
    J M Bos
    Groningen University Institute for Drug Exploration Groningen Research Institute for Pharmacy GUIDE GRIP, The Netherlands
    Pharmacoeconomics 19:937-46. 2001
    ....
  73. ncbi The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach
    J M Bos
    Graduate Schools SHARE and GUIDE, Groningen Research Institute of Pharmacy GRIP, University of Groningen, Groningen, The Netherlands
    Vaccine 25:6922-9. 2007
    ..However, if evidence on relevant RSV-related mortality would become available, higher pricing would be justified, while still remaining below accepted thresholds for cost-effectiveness...
  74. ncbi Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program
    J M Bos
    Department of Health Services Research, National Institute of Public Health and the Environment, P O Box 1, 3720 BA, Bilthoven, The Netherlands
    Vaccine 20:202-7. 2001
    ..These results are sensitive to the vaccine dose price (conservatively estimated at 10), efficacy, and coverage of meningococcal sero-subtypes...
  75. ncbi Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model
    Mark H Rozenbaum
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    BMC Public Health 11:462. 2011
    ..We aimed to investigate which factors had a major impact on cost-effectiveness and were primarily responsible for the large differences in previously estimated cost-effectiveness ratios...
  76. ncbi Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model
    Robin de Vries
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    PLoS ONE 5:e13392. 2010
    ..Using this framework, we estimate the cost-effectiveness of universal adolescent pertussis booster vaccination at the age of 12 years in the Netherlands...
  77. ncbi Quantification of the potential impact of cost-effectiveness thresholds on dutch drug expenditures using retrospective analysis
    Cornelis Boersma
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Value Health 13:853-6. 2010
    ..Yet, since 2005, all new innovative do have to go through a cost-effectiveness evaluation though, with the assessment being focused on the methodology rather than on the exact cost-per-QALY outcome...
  78. ncbi Analyzing generic and branded substitution patterns in the Netherlands using prescription data
    Petros Pechlivanoglou
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, A, Deusinglaan 1, 9713 AV Groningen, The Netherlands
    BMC Health Serv Res 11:89. 2011
    ..We aim to analyse the extent and nature of substitution in recent years and estimate the likelihood of generic or branded substitution in Dutch pharmacies in relation to various characteristics...
  79. ncbi Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis
    Stefan Vegter
    Department of Pharmacy, Unit of PharmacoEpidemiology and PharmacoEconomics PE 2, University of Groningen, Groningen, The Netherlands
    Value Health 14:852-8. 2011
    ..We determined the cost-effectiveness of the noncalcium-based phosphate binder lanthanum carbonate (LC) as second-line treatment of hyperphosphatemia after therapy failure with calcium-based binders (CB)...
  80. ncbi Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines
    Stefan Vegter
    Groningen Research Institute of Pharmacy GRIP, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 26:569-87. 2008
    ..For these goals, we provide a list of recommendations for good pharmacoeconomic practice deemed useful in the fields of pharmacogenetics and pharmacogenomics, regardless of country and origin of the economic analysis...
  81. ncbi International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference
    Maarten J Postma
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Pharmacoecon Outcomes Res 9:305-7. 2009
    ....
  82. ncbi Economics of assisted reproduction: access to fertility treatments and valuing live births in economic terms
    Mark P Connolly
    Department of Pharmacy, Unit of Pharmacoepidemiology and Pharmacoeconomics, University of Groningen, Groningen, The Netherlands
    Hum Fertil (Camb) 13:13-8. 2010
    ....
  83. ncbi Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening
    J A Land
    Department of Obstetrics and Gynaecology, University Medical Center Groningen, Groningen, The Netherlands
    Hum Reprod Update 16:189-204. 2010
    ..There is considerable debate over the exact complication rates after chlamydia infections, and more precise estimates of PID and tubal infertility are needed, for instance to be inserted in economic models...
  84. ncbi Cost-effectiveness of HIV screening of patients attending clinics for sexually transmitted diseases in Amsterdam
    J M Bos
    Groningen University for Drug Exploration/Groningen Research Institute for Pharmacy GUIDE/GRIP, Groningen, The Netherlands
    AIDS 15:2031-6. 2001
    ..CONCLUSION: Compared to other interventions in infectious diseases control in the Netherlands, screening of STD clinic attendees for HIV has an acceptable cost-effectiveness...
  85. ncbi The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life
    G A A Hubben
    University Center for Pharmacy, University of Groningen, Groningen, The Netherlands
    AIDS Care 20:449-55. 2008
    ..The costs of inpatient care in our cohort were almost negligible compared to total costs. Despite being in treatment, many patients were still gainfully employed and generated substantial expected annual earnings...
  86. ncbi Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands
    M J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Groningen, The Netherlands
    Transfus Med 15:379-87. 2005
    ..Validation of several crucial parameters is required, in particular the Dutch risk for acquiring and dying of transfusion-related sepsis...
  87. ncbi Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands)
    M J Postma
    Groningen University Institute for Drug Exploration/University of Groningen Research Institute of Pharmacy (GUIDE/GRIP, Groningen, The Netherlands
    Vaccine 22:1862-7. 2004
    ..Such a vaccination program fits into the recent Dutch policy of specific vaccinations directed at groups of ethnic minorities, such as for hepatitis B...
  88. ncbi Cost-effectiveness of leucocyte-depleted erythrocyte transfusion in cardiac valve surgery
    M van Hulst
    Department of Social Pharmacy, Pharmaco epidemiology and Pharmacotherapy Groningen University Institute for Drug Exploration Groningen Research Institute of Pharmacy GUIDE GRIP, The Netherlands
    Transfus Med 15:209-17. 2005
    ..Leucodepletion of erythrocytes is a cost-saving strategy in cardiac valve (+/-CABG) patients. However, probablistic analysis failed to show a significant difference with buffy-coat-depleted PC...
  89. ncbi Excess drug prescriptions during influenza and RSV seasons in the Netherlands: potential implications for extended influenza vaccination
    M D M Assink
    Unit of PharmacoEpidemiology and PharmacoEconomics PE 2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Vaccine 27:1119-26. 2009
    ..In particular, extension of influenza vaccination to groups of non-elderly adults and young children may lower excess prescriptions during these influenza periods for all three types of drug prescriptions investigated...
  90. ncbi Switch patterns before and after patent expiry of omeprazole: a case study in The Netherlands
    R M Klok
    Department of Social Pharmacy, Pharmaco epidemiology and Pharmacotherapy, Groningen University Institute for Drug Exploration GUIDE, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Aliment Pharmacol Ther 23:1595-600. 2006
    ..To evaluate influences of patent expiry on therapeutic substitution, switch behaviour before and after patent expiry was investigated...
  91. ncbi Economic evaluations of hepatitis B vaccination for developing countries
    Hong Anh T Tu
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 8:907-20. 2009
    ....
  92. ncbi Costs of chemotherapy in the treatment of colorectal cancer
    F G A Jansman
    Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen University Institute for Drug Exploration (GUIDE, Groningen, Netherlands
    Eur J Health Econ 7:145-6. 2006
  93. ncbi The impact of introducing patient co-payments in Germany on the use of IVF and ICSI: a price-elasticity of demand assessment
    M P Connolly
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Hum Reprod 24:2796-800. 2009
    ..In 2004 German health authorities introduced a 50% co-payment for patients, in an effort to save cost. We explored the impact of this pricing policy on the utilization of reproductive treatments in Germany...
  94. ncbi Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria
    Maarten J Postma
    Nephrol Dial Transplant 23:1103-6. 2008
  95. ncbi A multicentre study of patient survival, disability, quality of life and cost of care: among patients with AIDS in northern Italy
    Andrea Tramarin
    Department of Infectious Diseases and Tropical Medicine, San Bortolo Hospital, Vicenza, Italy
    Pharmacoeconomics 22:43-53. 2004
    ..To describe the epidemiological, clinical and economic changes that occurred in the HIV epidemic in Italy prior to and after the introduction of highly active antiretroviral therapy (HAART)...
  96. ncbi Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States
    Christopher E Bell
    Abt Associates Inc, Health Economic Research and Quality of Life Evaluation Services, Bethesda, Maryland, USA
    Clin Ther 25:2464-86. 2003
    ..The IBS for platelets may be considered a desirable strategy to increase the safety of platelet transfusions and a potential insurance against the threat of emerging pathogens...
  97. ncbi A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands
    Ben A van Hout
    Dutch Center for Health Economics and System Science, Capelle aan de Issel, The Netherlands
    Clin Ther 25:635-46. 2003
    ..However, this is only true if the substitution of omeprazole by pantoprazole can be achieved without loss of efficacy or tolerability...
  98. ncbi Incremental cost-effectiveness of cyclooxygenase 2-selective versus nonselective nonsteroidal anti-inflammatory drugs in a cohort of coumarin users: a pharmacoeconomic analysis linked to a case-control study
    Ellen A J Knijff-Dutmer
    Medisch Spectrum Twente, Enschede, Netherlands
    Clin Ther 26:1160-7. 2004
    ....
  99. ncbi Cost-effectiveness of screening for proteinuria
    Ron T Gansevoort
    JAMA 291:1442-3; author reply 1443. 2004
  100. ncbi The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine
    Robert Welte
    Institute of Health Economics and Health Care Management, GSF National Research Center for Environment and Health, Neuherberg, Germany
    Pharmacoeconomics 23:855-74. 2005
    ..In order to improve the international comparability of such studies, firmer national and international modelling guidelines and better adherence to such guidelines seem necessary...
  101. ncbi Cost-effectiveness of antenatal HIV-testing: reviewing its pharmaceutical and methodological aspects
    Maarten J Postma
    Groningen University
    Expert Opin Pharmacother 5:521-8. 2004
    ....